Mallinckrodt/Epix MS-325 vascular MRI imaging agent nearing Phase II -- Epix offering prospectus.
Executive Summary
EPIX MEDICAL MS-325 VASCULAR IMAGING AGENT PHASE II TRIALS will test the agent's ability to enhance magnetic resonance imaging of arteries and veins as an alternative to X-ray angiography, Epix Medical said in a recent initial public offering prospectus. The company believes that MS-325 may have applications in diagnosis of coronary artery disease, peripheral vascular disease and thrombosis. Epix is developing MS-325 in collaboration with Mallinckrodt.